Kiadis Pharma is a dedicated oncology product development company, with four proprietary products in various stages of clinical development. With leading oncologists participating in our clinical programs, an ongoing external validation of Kiadis Pharma’s technologies and products is ensured. The clinical programs are supported by three proprietary technology platforms, securing an abundant feed of the pipeline. The drive to accomplish the strategic growth of Kiadis Pharma as a Dutch-Canadian enterprise is endorsed by our investors, academic partners and a cross-Atlantic management team, uniting all expertise to bring products to market. The platforms, Theralux™, ECTA and BioSelact™, have the proven capacity to generate product candidates, as exemplified by the current investigational treatments. For the future, these technology platforms will ensure an uninterrupted feed of novel products to replenish the pipeline. The Kiadis Pharma technology is diverse and covers both a rational drug design approach and a broad high resolution screening approach. A broad IP portfolio protects Kiadis Pharma’s products and technologies.
Kiadis pharma
Zernikepark 6-8, 9747 AN Groningen, The Netherlands, t +31 (0) 50 547 42 70, f +31 (0) 50 547 42 71.
2525 ave. Marie-Curie, Saint-Laurent (Quebec), Canada H4S 2E1, t +1 (514) 336-4886, f +1 (514) 336-7329
